1. 78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. (10th December 2020) Authors: Ye, Dingwei; Zhou, Aiping; Zou, Qing; Li, Hanzhong; Fu, Cheng; Hu, Hailong; Huang, Jian; Shen, Wei; Zhang, Yun; Ma, Xiaopeng; Zhang, Pei; Huang, Ruiqi; Qiu, Xiusong; Zhang, Lilin; Bi, Feng Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. (9th November 2020) Authors: Ye, Dingwei; Zhou, Aiping; Zou, Qing; Li, Hanzhong; Fu, Cheng; Hu, Hailong; Huang, Jian; Shen, Wei; Zhang, Yun; Ma, Xiaopeng; Zhang, Pei; Huang, Ruiqi; Qiu, Xiusong; Zhang, Lilin; Bi, Feng Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer. (18th January 2021) Authors: Sheng, Haoyue; Zhang, Guiming; Huang, Yongqiang; Sun, Lijiang; Shi, Guohai; Ye, Dingwei Other Names: Meng Xiang-Yu Academic Editor. Journal: Disease markers Issue: Volume 2021(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A functional variant in TP63 at 3q28 associated with bladder cancer risk by creating an miR‐140‐5p binding site. Issue 1 (18th January 2016) Authors: Wang, Meilin; Du, Mulong; Ma, Lan; Chu, Haiyan; Lv, Qiang; Ye, Dingwei; Guo, Jianming; Gu, Chengyuan; Xia, Guowei; Zhu, Yao; Ding, Qiang; Yuan, Lin; Fu, Guangbo; Tong, Na; Qin, Chao; Yin, Changjun; Xu, Jianfeng; Zhang, Zhengdong Journal: International journal of cancer Issue: Volume 139:Issue 1(2016:Jul. 01) Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China. Issue 3 (15th March 2019) Authors: He, Dalin; Sun, Zhongquan; Guo, Jianming; Zhang, Zhigen; Shan, Yuxi; Ma, Lulin; Li, Hanzhong; Jin, Jie; Huang, Yiran; Xiao, Jiaquan; Wei, Qiang; Ye, Dingwei Journal: Asia-Pacific journal of clinical oncology Issue: Volume 15:Issue 3(2019) Page Start: 144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. (1st January 2020) Authors: Shao, Ning; Tang, Hong; Mi, Yuanyuan; Zhu, Yao; Wan, Fangning; Ye, Dingwei Journal: Oncoimmunology Issue: Volume 9:Number 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. (1st January 2020) Authors: Shao, Ning; Tang, Hong; Mi, Yuanyuan; Zhu, Yao; Wan, Fangning; Ye, Dingwei Journal: Oncoimmunology Issue: Volume 9:Number 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A novel Germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men1. Issue 2 (21st June 2012) Authors: Lin, Xiaoling; Qu, Lianxi; Chen, Zhuo; Xu, Chuanliang; Ye, Dingwei; Shao, Qiang; Wang, Xiang; Qi, Jun; Chen, Zhiwen; Zhou, Fangjian; Wang, Meilin; Wang, Zhong; He, Dalin; Wu, Denglong; Gao, Xin; Yuan, Jianlin; Wang, Gongxian; Xu, Yong; Wang, Guozeng; Dong, Pei Journal: Prostate Issue: Volume 73:Issue 2(2013) Page Start: 169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Abiraterone acetate for metastatic castration‐resistant prostate cancer after docetaxel failure: A randomized, double‐blind, placebo‐controlled phase 3 bridging study. (15th February 2016) Authors: Sun, Yinghao; Zou, Qing; Sun, Zhongquan; Li, Changling; Du, Chuanjun; Chen, Zhiwen; Shan, Yuxi; Huang, Yiran; Jin, Jie; Ye, Zhang Qun; Xie, Liping; Lin, Guowen; Feng, Yi; De Porre, Peter; Liu, Weiping; Ye, Dingwei Journal: International journal of urology Issue: Volume 23:Number 5(2016) Page Start: 404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Issue 5 (May 2019) Authors: Fizazi, Karim; Tran, NamPhuong; Fein, Luis; Matsubara, Nobuaki; Rodriguez-Antolin, Alfredo; Alekseev, Boris Y; Özgüroğlu, Mustafa; Ye, Dingwei; Feyerabend, Susan; Protheroe, Andrew; Sulur, Giri; Luna, Yesenia; Li, Susan; Mundle, Suneel; Chi, Kim N Journal: Lancet oncology Issue: Volume 20:Issue 5(2019) Page Start: 686 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗